Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease-Reference-Cited by-同舟云学术

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease

Published:2014-04 Issue:15 Volume:63 Page:1500-1509
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Angiolillo Dominick J.,Curzen Nicholas,Gurbel Paul,Vaitkus Paul,Lipkin Fred,Li Wei,Jakubowski Joseph A.,Zettler Marjorie,Effron Mark B.,Trenk Dietmar

Funder

Daiichi Sankyo, Inc., and Eli Lilly and Company

Bristol-Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, Otsuka, Eli Lilly, Daiichi Sankyo, Inc., The Medicines Company, AstraZeneca, Evolva, and Gilead

Haemonetics, St. Jude Medical, and Medtronic

National Institutes of Health, Daiichi Sankyo, Inc., Lilly, Pozen, CSL, AstraZeneca, Haemoscope Corporation, Harvard Clinical Research Institute, and Duke Clinical Research Institute

Eli Lilly

Daiichi Sankyo, Inc

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

2. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions;Levine;J Am Coll Cardiol,2011

3. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;O'Gara;J Am Coll Cardiol,2013

4. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives;Angiolillo;J Am Coll Cardiol,2007

5. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study;Stone;Lancet,2013

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention;JACC: Cardiovascular Interventions;2023-10

2. Ticagrelor inverse agonist activity at the P2Y₁₂ receptor is non‐reversible versus its endogenous agonist adenosine 5´‐diphosphate;British Journal of Pharmacology;2023-09

3. Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor;JACC: Cardiovascular Interventions;2023-01

4. New Approaches in P2Y12 Receptor Blocker Drugs Use;Frontiers in Cardiovascular Drug Discovery;2022-11-09

5. Clinical pharmacology of antiplatelet drugs;Expert Review of Clinical Pharmacology;2022-09-11